文献速递白血病造血干细胞移植与细胞治疗

干细胞表观基因组与儿童急性淋巴细胞白血病中CD19 CAR-T细胞原发性无反应相关

A stem cell epigenome is associated with primary nonresponse to CD19 CAR T cells in pediatric acute lymphoblastic leukemia.
PubMed 文献 · Blood Adv · 2023-01-01

该研究对西雅图儿童医院PLAT-02试验中14例患者(7例原发无反应、7例原发敏感)采用多组学方法,发现原发无反应白血病存在PRC2靶基因DNA高甲基化、染色质可及性降低及干细胞特征区域可及性增加,并鉴定出表达多系标志和抗原提呈降低的白血病亚群,提示干细胞表观基因组与CD19 CAR-T原发耐药相关。

要点

  • 原发无反应白血病在治疗前即存在PRC2靶基因DNA高甲基化和染色质可及性降低。
  • 原发无反应中可见造血干细胞和多系祖细胞特征区域染色质可及性增加。
  • 单细胞分析显示原发无反应白血病亚群表达多系标志且抗原提呈降低。

核心结论

  • 研究描述了干细胞表观基因组与CD19 CAR-T治疗原发耐药之间的关联。
  • 作者提出未来试验可结合这些生物标志物、靶向白血病干细胞或多系抗原的多特异性CAR-T细胞和/或表观遗传治疗以改善B-ALL患者结局。

研究设计与样本

  • 研究纳入西雅图儿童医院PLAT-02试验中14例患者,其中7例原发无反应、7例原发敏感。
  • 采用多组学方法,包括长读长PacBio测序、表观遗传谱分析、转座酶可及染色质测序、单细胞RNA测序和飞行时间流式细胞术。

主要发现

  • 长读长PacBio测序发现1例原发无反应患者中47%的CD19转录本存在外显子2跳跃,其他样本未见CD19转录本异常。
  • 表观遗传谱分析发现原发无反应中胚胎干细胞多梳抑制复合体2(PRC2)靶基因存在DNA高甲基化。
  • 转座酶可及染色质测序显示原发无反应中PRC2靶基因可及性降低,而造血干细胞和多系祖细胞特征区域可及性增加。
  • 单细胞RNA测序和飞行时间流式细胞术分析鉴定出原发无反应中表达多系标志且抗原提呈降低的白血病亚群。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CD19 chimeric antigen receptor T-cell therapy (CD19-CAR) has changed the treatment landscape and outcomes for patients with pre-B-cell acute lymphoblastic leukemia (B-ALL). Unfortunately, primary nonresponse (PNR), sustained CD19+ disease, and concurrent expansion of CD19-CAR occur in 20% of the patients and is associated with adverse outcomes. Although some failures may be attributable to CD19 loss, mechanisms of CD19-independent, leukemia-intrinsic resistance to CD19-CAR remain poorly understood. We hypothesize that PNR leukemias are distinct compared with primary sensitive (PS) leukemias and that these differences are present before treatment. We used a multiomic approach to investigate this in 14 patients (7 with PNR and 7 with PS) enrolled in the PLAT-02 trial at Seattle Children's Hospital. Long-read PacBio sequencing helped identify 1 PNR in which 47% of CD19 transcripts had exon 2 skipping, but other samples lacked CD19 transcript abnormalities. Epigenetic profiling discovered DNA hypermethylation at genes targeted by polycomb repressive complex 2 (PRC2) in embryonic stem cells. Similarly, assays of transposase-accessible chromatin-sequencing revealed reduced accessibility at these PRC2 target genes, with a gain in accessibility of regions characteristic of hematopoietic stem cells and multilineage progenitors in PNR. Single-cell RNA sequencing and cytometry by time of flight analyses identified leukemic subpopulations expressing multilineage markers and decreased antigen presentation in PNR. We thus describe the association of a stem cell epigenome with primary resistance to CD19-CAR therapy. Future trials incorporating these biomarkers, with the addition of multispecific CAR T cells targeting against leukemic stem cell or myeloid antigens, and/or combined epigenetic therapy to disrupt this distinct stem cell epigenome may improve outcomes of patients with B-ALL.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Masih KE, Gardner RA, Chou HC, et al. A stem cell epigenome is associated with primary nonresponse to CD19 CAR T cells in pediatric acute lymphoblastic leukemia. Blood Adv. 2023. PMID: 36607839. doi:10.1182/bloodadvances.2022008977

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。